HIGH

Graviti Pharmaceuticals Bupropion Hydrochloride XL 300 mg Recall Impacts 46,512 Bottles (2025)

Graviti Pharmaceuticals Private Limited manufactured Bupropion Hydrochloride Extended-Release Tablets XL 300 mg, distributed nationwide by Rising Pharma Holdings, Inc., in 46,512 bottles. The recall cites failed tablet specifications. Stop using the product immediately and contact the manufacturer or your healthcare provider for guidance.

Quick Facts at a Glance

Recall Date
September 15, 2025
Hazard Level
HIGH
Brands
Bupropion Hydrochloride, Rising Pharma Holdings, Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

Failed Tablet/Capsule Specifications

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Graviti Pharmaceuticals Private Limited or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Bupropion hydrochloride extended-release tablets are used as antidepressants and for smoking cessation support in certain regimens. The XL formulation provides a longer dosing interval for some patients.

Why This Is Dangerous

A manufacturing defect causing failed tablet specifications can lead to incorrect dosing or variable drug release, potentially impacting treatment effectiveness or safety.

Industry Context

This recall is not described as part of a broader industry pattern in the provided information.

Real-World Impact

Patients may experience treatment disruption or require dose adjustments if the product is not dosed as intended. The issue is a quality control problem rather than an immediate physical hazard.

Practical Guidance

How to identify if yours is affected

  1. Check the bottle label for NDC 16571-863-03.
  2. Check batch BPB124341A on the bottle or packaging.
  3. Verify expiration date 10/2026.
  4. Confirm bottle count is 30 tablets per bottle and total quantity recalled 46,512.

Where to find product info

NDC and batch numbers are printed on the bottle label and packaging. The recall notice links to enforcement reports with details.

What timeline to expect

Recall status is ACTIVE as of the report date; refunds or replacements are not explicitly described in the notice. Follow manufacturer guidance for a回

If the manufacturer is unresponsive

  • Contact Graviti Pharmaceuticals Private Limited for guidance.
  • If the company is unresponsive, escalate to FDA MedWatch or the appropriate national regulatory body.

How to prevent similar issues

  • Always verify NDC, batch, and expiration before using prescription meds.
  • Buy Rx meds from licensed pharmacies only.
  • Keep a record of recalls and batch information for future reference.

Documentation advice

Keep recall notices, bottle packaging, receipts, and any correspondence with the manufacturer or distributor.

Product Details

NDC: 16571-863-03 Batch: BPB124341A Exp: 10/2026 Quantity recalled: 46,512 bottles Package: 30-count bottles, Rx Only Manufactured by: Graviti Pharmaceuticals Private Limited, Sangareddy, Telangana, India Distributed by: Rising Pharma Holdings, Inc. Sold to: 1 distributor and 16 wholesalers/pharmacy retailers nationwide Recall date: 2025-09-15 Status: ACTIVE

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 46,512 bottles recalled
  • NDC 16571-863-03
  • Batch BPB124341A
  • Exp 10/2026
  • 1 distributor and 16 wholesalers/pharmacy retailers nationwide
  • Rx Only

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
BPB124341A
Exp date: 10/2026
UPC Codes
16571-862
16571-863
16571-862-03
+8 more
Affected States
ALL
Report Date
October 29, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more
Vehicles & Parts
HIGH

Chrysler Pacifica Radio Recall 2025 Over Rearview Camera Display Issue

Chrysler is recalling 2024-2025 Pacifica minivans after a radio installed during production could fail to display the rearview camera image. Dealers will replace the radio at no cost. Owner letters were mailed August 7, 2025. Contact Chrysler customer service at 800-853-1403 for details.

Chrysler
A rearview
Read more